Cyto-Facto Inc. announced that it has received ¥1.2 billion in funding from MPower Partners GP Limited, Asahi Kasei Corporation, FUJIFILM Holdings Corporation, Sumitomo Corporation
Published on 13/06/2025 at 03:30
Share
Cyto-Facto Inc. announced that it has received ¥1,200 million in a round of funding on June 13, 2025. The transaction included participation from returning investors, MPower Partners GP Limited, Asahi Kasei Corporation, new investors, FUJIFILM Holdings Corporation and Sumitomo Corporation. The company has issued common shares through third party allotment method and has raised ¥2,700 million in its funding till date.
Fujifilm Holdings Corp is a Japan-based company engaged in the healthcare, materials, business innovation, and imaging businesses. The Company operates through four business segments. The Healthcare segment develops, manufactures, sells, and services medical system equipment, contract manufacturing and development of biopharmaceuticals, drug discovery support materials such as cells, culture media, and reagents, pharmaceuticals, cosmetics, and supplements. The Materials segment develops, manufactures, sells, and services electronic materials, display materials, industrial materials, fine chemicals, graphic communication system materials, and inkjet materials. The Business Innovation segment develops, manufactures, sells, and services digital multifunction devices, solutions, and services. The Imaging segment develops, manufactures, sells, and services instant photo systems, color films, color paper, services, and equipment for photo printing, digital cameras, and optical devices.
Cyto-Facto Inc. announced that it has received ¥1.2 billion in funding from MPower Partners GP Limited, Asahi Kasei Corporation, FUJIFILM Holdings Corporation, Sumitomo Corporation
